Artemis Bioservices is a private, non-profit CRO specialized in vaccine and antiviral evaluation. 

Vision of Artemis Bioservices: The vision of Artemis Bioservices is to become a strategic partner in the process of antiviral, antibody and vaccine development against emerging viral diseases. 

Mission of Artemis Bioservices: To assist biotech and biopharmaceutical companies to accelerate the development and licensing of safe and effective antiviral intervention strategies, in particular against emerging, zoonotic and arboviral diseases, by offering customized in-vitro testing and in-vivo immunogenicity and efficacy testing capabilities

Artemis Bioservices provides high quality preclinical and clinical services to developers of antiviral intervention strategies who want to evaluate the immunogenicity and efficacy of candidate products, especially against emerging, vector-borne and zoonotic viruses. Artemis Bioservices has recently been certified GLP compliant. 

Artemis Bioservices is located in the Yes!Delft Labs building, at Molengraaffsingel 10, 2629 JD, Delft, The Netherlands.

Biotechnology

Life Sciences

Pharmaceutical

Artemis Bioservices (formerly known as Artemis Bio-Support)

Byron Martina

Ruud Van Hofwegen

Martin Schutten

The Research and Development Team at Artemis Bioservices focuses on designing and conducting rigorous preclinical studies to evaluate the immunogenicity and efficacy of novel antiviral candidates and vaccines. They collaborate closely with biotech and biopharmaceutical partners to customize testing protocols that address specific emerging viral threats, ensuring adherence to GLP standards. Through innovative methodologies and expertise, the team aims to accelerate the development timelines for safe and effective antiviral strategies.

Research and Development Team

About

Team members

Other teams at Artemis Bioservices (formerly known as Artemis Bio-Support)

Leadership Team